Uric Acid Nephrolithiasis

Urologic Clinics of North America

Volumn 34, Issue 3, 2007, Pages 335-346

  Cameron, Mary Ann ^a   Sakhaee, Khashayar ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; FEBUXOSTAT; URIC ACID;

HUMAN; HYPERURICOSURIA; INSULIN RESISTANCE; LIFESTYLE; NEPHROLITHIASIS; PRIORITY JOURNAL; REVIEW; RISK FACTOR; STONE ANALYSIS; URIC ACID STONE; URINARY EXCRETION; URINE PH; URINE VOLUME;

HUMANS; NEPHROLITHIASIS; URIC ACID;

EID: 34547434229     PISSN: 00940143     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ucl.2007.05.001     Document Type: Review

References (81)

1. Scheele K. Examen chemicum calculi urinari. Opuscula 2 (1776) 73 [German]
2. Riese R.J., and Sakhaee K. Uric acid nephrolithiasis: pathogenesis and treatment. J Urol 148 3 (1992) 765-771
3. Mandel N.S., and Mandel G.S. Urinary tract stone disease in the United States veteran population II. Geographical analysis of variations in composition. J Urol 142 (1989) 1516-1521
4. Atsmon A., DeVries A., and Frank M. Uric acid lithiasis (1963), Elsevier, Amsterdam
5. Hossain R.Z., Ogawa Y., Hokama S., et al. Urolithiasis in Okinawa, Japan: a relatively high prevalence of uric acid stones. Int J Urol 10 8 (2003) 411-415
6. Hesse A., Schneider H.J., Berg W., et al. Uric acid dihydrate as urinary calculus component. Invest Urol 12 5 (1975) 405-409
7. Portis A.J., Hermans K., Culhane-Pera K.A., et al. Stone disease in the Hmong of Minnesota: initial description of a high-risk population. J Endourol 18 9 (2004) 853-857
8. Taylor E.N., Stampfer M.J., and Curhan G.C. Diabetes mellitus and the risk of nephrolithiasis. Kidney Int 68 3 (2005) 1230-1235
9. Pak C.Y.C., Sakhaee K., Moe O.W., et al. Biochemical profile of stone-forming patients with diabetes mellitus. Urology 61 (2003) 523-527
10. Daudon M., Lacour B., and Jungers P. High prevalence of uric acid calculi in diabetic stone formers. Nephrol Dial Transplant 20 2 (2005) 468-469
11. Daudon M., Traxer O., Conort P., et al. Type 2 diabetes increases the risk for uric acid stones. J Am Soc Nephrol 17 7 (2006) 2026-2033
12. Ekeruo W.O., Tan Y.H., Young M.D., et al. Metabolic risk factors and the impact of medical therapy on the management of nephrolithiasis in obese patients. J Urol 172 1 (2004) 159-163
13. Daudon M., Lacour B., and Jungers P. Influence of body size on urinary stone composition in men and women. Urol Res 34 3 (2006) 193-199
14. Cameron M.A., Maalouf N.M., Adams-Huet B., et al. Urine composition in type 2 diabetes: predisposition to uric acid nephrolithiasis. J Am Soc Nephrol 17 7 (2006) 1422-1428
15. Asplin J.R. Uric acid nephrolithiasis. Semin Nephrol 16 (1996) 412-424
16. Pak C.Y.C., Barilla D., Holt K., et al. Effect of oral purine load and allopurinol on the crystallization of calcium salts in urine of patients with hyperuricosuric calcium urolithiasis. Am J Med 65 (1978) 593-599
17. Fellstrom B., Danielson B.G., Karlstrom B., et al. The influence of a high dietary intake of purine-rich animal protein on urinary urate excretion and supersaturation in renal stone disease. Clin Sci 64 4 (1983) 399-405
18. Moe O.W., Abate N., and Sakhaee K. Pathophysiology of uric acid nephrolithiasis. Endocrinol Metab Clin North Am 31 (2002) 895-914
19. Rafey M.A., Lipkowitz M.S., Leal-Pinto E., et al. Uric acid transport. Curr Opin Nephrol Hypertens 12 5 (2003) 511-516
20. Coe F.L., Strauss A.L., Tembe V., et al. Uric acid saturation in calcium nephrolithiasis. Kidney Int 17 (1980) 662-668
21. Finlayson B., and Smith L.H. Stability of the first dissociable proton of uric acid. J Chem Engineering Data 19 (1974) 94-97
22. Wilcox W.R., Khalaf A., Weinberger A., et al. Solubility of uric acid and monosodium urate. Med Biol Eng 10 4 (1972) 522-531
23. Pak C.Y.C., Waters O., Arnold L., et al. Mechanism for calcium urolithiasis among patients with hyperuricosuria. J Clin Invest 59 (1977) 426-431
24. Pak C.Y., Holt K., and Zerwekh J.E. Attenuation by monosodium urate of the inhibitory effect of glycosaminoglycans on calcium oxalate nucleation. Invest Urol 17 2 (1979) 138-140
25. Pak C.Y.C., and Arnold L.H. Heterogeneous nucleation of calcium oxalate by seeds of monosodium urate. Proc Soc Exp Biol Med 149 (1975) 930-932
26. Coe F.L., Lawton R.L., Goldstein R.B., et al. Sodium urate accelerates precipitation of calcium oxalate in vitro. Proc Soc Exp Biol Med 149 (1975) 926-929
27. Lonsdale K. Epitaxy as a growth factor in urinary calculi and gallstones. Nature 217 123 (1968) 56-58
28. Sakhaee K., Nicar M., Hill K., et al. Contrasting effects of potassium citrate and sodium citrate therapies on urinary chemistries and crystallization of stone-forming salts. Kidney Int 24 3 (1983) 348-352
29. Sorensen L.B. Role of the intestinal tract in the elimination of uric acid. Arthritis Rheum 8 5 (1965) 694-706
30. Enomoto A., Kimura H., Chairoungdua A., et al. Molecular identification of a renal urate anion exchanger that regulates blood urate levels. Nature 417 6887 (2002) 447-452
31. Hediger M.A., Johnson R.J., Miyazaki H., et al. Molecular physiology of urate transport. Physiology (Bethesda) 20 (2005) 125-133
32. Ichida K., Hosoyamada M., Hisatome I., et al. Clinical and molecular analysis of patients with renal hypouricemia in Japan-influence of URAT1 gene on urinary urate excretion. J Am Soc Nephrol 15 1 (2004) 164-173
33. Sekine T., Watanabe N., Hosoyamada M., et al. Expression cloning and characterization of a novel multispecific organic anion transporter. J Biol Chem 272 30 (1997) 18526-18529
34. Cha S.H., Sekine T., Fukushima J.I., et al. Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney. Mol Pharmacol 59 5 (2001) 1277-1286
35. Welborn J.R., Shpun S., Dantzler W.H., et al. Effect of alpha-ketoglutarate on organic anion transport in single rabbit renal proximal tubules. Am J Physiol 274 1 Pt 2 (1998) F165-F174
36. Werner D., and Roch-Ramel F. Indirect Na+ dependency of urate and p-aminohippurate transport in pig basolateral membrane vesicles. Am J Physiol 261 2 Pt 2 (1991) F265-F272
37. Van Aubel R.A., Smeets P.H., van den Heuvel J.J., et al. Human organic anion transporter MRP4 (ABCC4) is an efflux pump for the purine end metabolite urate with multiple allosteric substrate binding sites. Am J Physiol Renal Physiol 288 2 (2005) F327-F333
38. Lipkowitz M.S., Leal-Pinto E., Rappoport J.Z., et al. Functional reconstitution, membrane targeting, genomic structure, and chromosomal localization of a human urate transporter. J Clin Invest 107 9 (2001) 1103-1115
39. Uchino H., Tamai I., Yamashita K., et al. p-aminohippuric acid transport at renal apical membrane mediated by human inorganic phosphate transporter NPT1. Biochem Biophys Res Commun 270 1 (2000) 254-259
40. Pak C.Y.C., Skurla C., and Harvey J. Graphic display of urinary risk factors for renal stone formation. J Urol 134 (1985) 867-870
41. Sakhaee K., Adams-Huet B., Moe O.W., et al. Pathophysiologic basis for normouricosuric uric acid nephrolithiasis. Kidney Int 62 (2002) 971-979
42. Alvarez-Nemegyei J., Medina-Escobedo M., Villanueva-Jorge S., et al. Prevalence and risk factors for urolithiasis in primary gout: is a reappraisal needed?. J Rheumatol 32 11 (2005) 2189-2191
43. Mineo I., Kono N., Hara N., et al. Myogenic hyperuricemia. A common pathophysiologic feature of glycogenosis types III, V, and VII. N Engl J Med 317 2 (1987) 75-80
44. Cameron J.S., Moro F., and Simmonds H.A. Gout, uric acid and purine metabolism in paediatric nephrology. Pediatr Nephrol 7 (1993) 105-118
45. Tanaka M., Itoh K., Matsushita K., et al. Two male siblings with hereditary renal hypouricemia and exercise-induced ARF. Am J Kidney Dis 42 6 (2003) 1287-1292
46. Yeun J.Y., and Hasbargen J.A. Renal hypouricemia: prevention of exercise-induced acute renal failure and a review of the literature. Am J Kidney Dis 25 6 (1995) 937-946
47. Maalouf N., Cameron M.A., Moe O.W., et al. Novel insights into the pathogenesis of uric acid nephrolithiasis. Curr Opin Nephrol Hypertens 13 (2004) 181-189
48. Shahinfar S., Simpson R.L., Carides A.D., et al. Safety of losartan in hypertensive patients with thiazide-induced hyperuricemia. Kidney Int 56 5 (1999) 1879-1885
49. Grossman M.S., and Nugent F.W. Urolithiasis as a complication of chronic diarrheal disease. Am J Dig Dis 12 5 (1967) 491-498
50. Sakhaee K., Nigam S., Snell P., et al. Assessment of the pathogenetic role of physical exercise in renal stone formation. J Clin Endocrinol Metab 65 5 (1987) 974-979
51. Reddy S.T., Wang C.Y., Sakhaee K., et al. Effect of low-carbohydrate high-protein diets on acid-base balance, stone-forming propensity, and calcium metabolism. Am J Kidney Dis 40 2 (2002) 265-274
52. Yu T.F., and Gutman A.B. Uric acid nephrolithiasis in gout: predisposing factors. Ann Intern Med 67 (1967) 1133-1148
53. Aruga S., Wehrli S., Kaissling B., et al. Chronic metabolic acidosis increases NaDC-1 mRNA and protein abundance in rat kidney. Kidney Int 58 (2000) 206-215
54. Abate N., Chandalia M., Cabo-Chan A.V., et al. The metabolic syndrome and uric acid nephrolithiasis: novel features of renal manifestation of insulin resistance. Kidney Int 65 (2004) 386-392
55. Maalouf N., Sakhaee K., Parks J.H., et al. Association of urinary pH with body weight in nephrolithiasis. Kidney Int 65 (2004) 386-392
56. Chen Y.D., Varasteh B.B., and Reaven G.M. Plasma lactate concentration in obesity and type 2 diabetes. Diabetes Metab 19 4 (1993) 348-354
57. Chobanian M.C., and Hammerman M.R. Insulin stimulates ammoniagenesis in canine renal proximal tubular segments. Am J Physiol 253 (1987) F1171-F1177
58. Nagami G.T. Luminal secretion of ammonia in the mouse proximal tubule perfused in vitro. The J Clin Invest 81 (1988) 159-164
59. + exchange activity in proximal tubules from normotensive and hypertensive rats. Am J Physiol 260 (1991) F695-F703
60. + exchanger 3: biphasic response and glucocorticoid dependence. Am J Physiol 283 (2002) F532-F539
61. Cameron M.A., Maalouf N.M., Abate N., et al. The renal acidification response to insulin differs between uric acid stone formers and normal subjects. [abstract]. J Am Soc Nephrol 15 Abstracts Issue (2004) 518A
62. Cameron M.A., and Pak C.Y.C. Approach to the patient with the first episode of nephrolithiasis. Clin Rev Bone Miner Metab 2 3 (2004) 265-278
63. Pais Jr. V.M., Lowe G., Lallas C.D., et al. Xanthine urolithiasis. Urology 67 5 (2006) 1084.e9-1084.e11
64. Sorensen C.M., and Chandhoke P.S. Hyperuricosuric calcium nephrolithiasis. Endocrinol Metab Clin North Am 31 4 (2002) 915-925
65. Pak C.Y.C., Poindexter J.R., Adams-Huet B., et al. Predictive value of kidney stone composition in the detection of metabolic abnormalities. Am J Med 115 (2003) 26-32
66. Pak C.Y.C., Poindexter J.R., Peterson R.D., et al. Biochemical distinction between hyperuricosuric calcium urolithiasis and gouty diathesis. Urol 60 (2002) 789-794
67. Food and Nutrition Board. 2002 Dietary reference intakes for energy, carbohydrate, fiber, fat, fatty acids, cholesterol, protein, and amino acids (micronutrients) (2002), National Academies Press, Washington, DC. p. 589-768. Available at: (http://books.nap.edu/catalog/10490.html)
68. Becker M.A., Schumacher Jr. H.R., Wortmann R.L., et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 353 23 (2005) 2450-2461
69. Pak C.Y.C., Sakhaee K., and Fuller C. Successful management of uric acid nephrolithiasis with potassium citrate. Kidney Int 30 (1986) 422-428
70. Freed S.Z. The alternating use of an alkalizing salt and acetazolamide in the management of cystine and uric acid stones. J Urol 113 1 (1975) 96-99
71. Coe F.L., Evan A., and Worcester E. Kidney stone disease. J Clin Invest 115 10 (2005) 2598-2608
72. Welch B.J., Graybeal D., Moe O.W., et al. Biochemical and stone risk profiles with topiramate treatment. Am J Kidney Dis 48 4 (2006) 555-563
73. Gordon E.E., and Sheps S.G. Effect of acetazolamide on citrate excretion and formation of renal calculi. N Engl J Med 256 26 (1957) 1215-1219
74. Lamb E.J., Stevens P.E., and Nashef L. Topiramate increases biochemical risk of nephrolithiasis. Ann Clin Biochem 41 Pt 2 (2004) 166-169
75. Kuo R.L., Moran M.E., Kim D.H., et al. Topiramate-induced nephrolithiasis. J Endourol 16 4 (2002) 229-231
76. Wabner C.L., and Pak C.Y.C. Effect of orange juice consumption on urinary stone risk factors. J Urol 149 (1993) 1405-1408
77. Goldfarb D.S., and Asplin J.R. Effect of grapefruit juice on urinary lithogenicity. J Urol 166 1 (2001) 263-267
78. Lemann Jr. J., Piering W.F., and Lennon E.J. Possible role of carbohydrate-induced calciuria in calcium oxalate kidney-stone formation. N Engl J Med 280 5 (1969) 232-237
79. Odvina C.V. Comparative value of orange juice versus lemonade in reducing stone-forming risk. Clin J Am Soc Nephrol 1 (2006) 1269-1274
80. Stamatelou K., Francis M.E., Jones C., et al. Time trends in reported prevalence of kidney stones in the United States: 1976-1994. Kidney Int 63 5 (2003) 1817-1823
81. Ford E.S., Giles W.H., and Dietz W.H. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Study. JAMA 287 3 (2002) 356-359